2022
Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia
Kwon J, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Chambers HF, Fowler VG, Huskins WC, Pettigrew M. Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia. The Journal Of Infectious Diseases 2022, 226: 1109-1119. PMID: 35249113, PMCID: PMC9492313, DOI: 10.1093/infdis/jiac082.Peer-Reviewed Original ResearchConceptsAAD groupAntibiotic-Associated DiarrheaCommunity-Acquired PneumoniaCommon side effectsStudy days 1Days of diarrheaPatient characteristicsAntibiotic therapyNineteen childrenStool samplesSide effectsDay 1Microbiome disruptionMicrobiota profilesGastrointestinal microbiotaMicrobiota characteristicsDiarrheaBacteroides speciesPneumoniaChildrenAntibioticsΒ-lactamsAADBaseline abundanceDysbiosisShort- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children
Williams DJ, Creech CB, Walter EB, Martin JM, Gerber JS, Newland JG, Howard L, Hofto ME, Staat MA, Oler RE, Tuyishimire B, Conrad TM, Lee MS, Ghazaryan V, Pettigrew MM, Fowler VG, Chambers HF, Zaoutis TE, Evans S, Huskins WC, Team A. Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children. JAMA Pediatrics 2022, 176: 253-261. PMID: 35040920, PMCID: PMC8767493, DOI: 10.1001/jamapediatrics.2021.5547.Peer-Reviewed Original ResearchConceptsChildhood community-acquired pneumoniaAntibiotic-associated adverse effectsShort-course strategyClinical responseAdverse effectsDouble-blind placebo-controlled clinical trialPlacebo-controlled clinical trialEnd pointDays of antibioticsEarly clinical improvementInadequate clinical responseOutpatient antibiotic therapyShorter antibiotic durationsSimilar clinical responseCommunity-Acquired PneumoniaPrimary end pointComposite end pointResolution of symptomsAntibiotic treatment strategiesSubset of childrenAntibiotic daysAntibiotic durationClinical improvementAntibiotic therapyInitial treatment
2016
Pseudomonas aeruginosa Colonization in the Intensive Care Unit: Prevalence, Risk Factors, and Clinical Outcomes
Harris AD, Jackson SS, Robinson G, Pineles L, Leekha S, Thom KA, Wang Y, Doll M, Pettigrew MM, Johnson JK. Pseudomonas aeruginosa Colonization in the Intensive Care Unit: Prevalence, Risk Factors, and Clinical Outcomes. Infection Control And Hospital Epidemiology 2016, 37: 544-548. PMID: 26832307, PMCID: PMC4833506, DOI: 10.1017/ice.2015.346.Peer-Reviewed Original ResearchConceptsIntensive care unitPseudomonas aeruginosa colonizationRisk factorsICU admissionClinical culturesCurrent hospitalizationAeruginosa colonizationCare unitIntensive care unit admissionP. aeruginosaSurgical intensive care unitPositive clinical cultureCare unit admissionEmpirical antibiotic therapyTertiary care hospitalType of ICUSignificant risk factorsP. aeruginosa colonizationRapid diagnostic testingPerirectal surveillance culturesUnit admissionCohort studyAntibiotic therapyCare hospitalClinical outcomes